197 related articles for article (PubMed ID: 9723311)
1. Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation.
Gridelli B; Colledan M; Lucianetti A; Ulla L; Riva S; Segalin A; Fassati LR; Torre G
Transplant Proc; 1998 Aug; 30(5):1861-2. PubMed ID: 9723311
[No Abstract] [Full Text] [Related]
2. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
Melter M; Rodeck B; Kardorff R; Hoyer PF; Maibücher A; Brodehl J
Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
[No Abstract] [Full Text] [Related]
3. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression.
Reggiani P; Rossi G; Latham L; Caccamo L; Gatti S; Maggi U; Melada E; Paone G; Doglia M; Vannelli A; Fassati LR
Transplant Proc; 1998 Aug; 30(5):1855-6. PubMed ID: 9723308
[No Abstract] [Full Text] [Related]
4. Microemulsion cyclosporine (Neoral) immunosuppression for orthotopic liver transplantation in children reduces hospital stay.
Arumugam R; Soriano HE; Scheimann AO; Reid BS; Gopalakrishna GS; Barakat O; Ozaki CF; Wood RP
Transplant Proc; 1998 Aug; 30(5):1848-9. PubMed ID: 9723304
[No Abstract] [Full Text] [Related]
5. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients.
Ogino S; Hashikura Y; Katsuyama Y; Ikegami T; Nakazawa Y; Urata K; Terada M; Miyagawa S; Kawasaki S
Transplant Proc; 2004 Mar; 36(2 Suppl):299S-301S. PubMed ID: 15041357
[TBL] [Abstract][Full Text] [Related]
6. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation.
Bilbao I; Pou L; Allende E; Lázaro JL; Charco R; Hidalgo E; Margarit C
Transplant Proc; 2001 May; 33(3):2124-6. PubMed ID: 11377472
[No Abstract] [Full Text] [Related]
7. Results of conversion from Sandimmune to Neoral in stable pediatric liver transplant recipients after two years.
Dunn SP; Falkenstein K; Pierson A; Cooney GF
Transplant Proc; 1998 Aug; 30(5):1962-3. PubMed ID: 9723353
[No Abstract] [Full Text] [Related]
8. Potential role of Neoral in pediatric liver transplantation.
Whitington PF; Alonso EM; Millis JM
Transplant Proc; 1996 Aug; 28(4):2267-9. PubMed ID: 8769221
[No Abstract] [Full Text] [Related]
9. Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation.
Alberti D; Reding R; Otte JB; Falchetti D; Rigamonti W; Caccia G; Sokal E; de Ville de Goyet J
Transplant Proc; 1998 Aug; 30(5):1858-60. PubMed ID: 9723310
[No Abstract] [Full Text] [Related]
10. NOF-11: a one-year randomized double-blind comparison of Neoral versus Sandimmune in pediatric liver transplantation.
Alvarez F; Atkison P; Grant D; Jones A; Kim P; Kneteman N; Laurin L; Martin S; Paradis K; Shapiro J; Smith L; Superina R; Tan A
Transplant Proc; 1998 Aug; 30(5):1961. PubMed ID: 9723352
[No Abstract] [Full Text] [Related]
11. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group.
Peeters P; Kazek M; Abella I; Noble I
Transplant Proc; 1998 Aug; 30(5):1838-42. PubMed ID: 9723301
[No Abstract] [Full Text] [Related]
12. Increased dosage requirement and rejection after Neoral conversion in pediatric liver transplant patients.
Cao S; Cox KL; Berquist W; So S; Concepcion W; Monge H; Esquivel CO
Transplant Proc; 1998 Dec; 30(8):4322-4. PubMed ID: 9865373
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations.
Yasuhara M; Hashida T; Toraguchi M; Hashimoto Y; Kimura M; Inui K; Hori R; Inomata Y; Tanaka K; Yamaoka Y
Transplant Proc; 1995 Feb; 27(1):1108-10. PubMed ID: 7533356
[No Abstract] [Full Text] [Related]
14. Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient.
Falkenstein K; Dunn S
Transplant Proc; 1998 Aug; 30(5):1964-6. PubMed ID: 9723354
[No Abstract] [Full Text] [Related]
15. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients.
Jain AB; Fung JJ; Tzakis AG; Venkataramanan R; Abu-Elmagd K; Alessiani M; Reyes J; Irish W; Warty V; Mehta S
Transplant Proc; 1991 Dec; 23(6):2763-6. PubMed ID: 1721270
[No Abstract] [Full Text] [Related]
16. Experience with neoral cyclosporine through the oral route in liver transplantation.
Bilbao I; Lazaro JL; Pou L; Charco R; Hildalgo E; Murio E; Margarit C
Transplant Proc; 1998 Jun; 30(4):1432-4. PubMed ID: 9636580
[No Abstract] [Full Text] [Related]
17. Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression.
Mirza DF; Gunson BK; Soonawalla Z; Pirenne J; Mayer AD; Buckels JA; McMaster P
Lancet; 1997 Mar; 349(9053):701-2. PubMed ID: 9078209
[No Abstract] [Full Text] [Related]
18. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine.
Sato K; Yokota K; Matsui T; Imai K; Takishima T; Nakayama Y; Osakabe T; Yoshida M; Mieno H; Omiya H
Transplant Proc; 1991 Dec; 23(6):3296-9. PubMed ID: 1721440
[No Abstract] [Full Text] [Related]
19. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients.
Lagget M; Marzano A; Actis GC; Leone N; Ciancio A; Salizzoni M; Rizzetto M
Transplant Proc; 1998 Aug; 30(5):1863-4. PubMed ID: 9723312
[No Abstract] [Full Text] [Related]
20. Safety of conversion from cyclosporine Sandimmune to cyclosporine Neoral in stable liver transplant patients.
Baruch Y; Assy N; Kramsky R; Enat R
Transplant Proc; 1998 Aug; 30(5):1852-3. PubMed ID: 9723306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
